biogen eisai - Search News

Biogen, CHMP and Eisai

Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that will apply to all EU member states as well as Norway, Liechtenstein and Iceland.

Reuters · 3d

EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's drug, Leqembi, after concluding a safety review.

MarketWatch · 3d

Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi.

Business Insider · 3d

Biogen, Eisai announces CHMP of EMA reaffirmed positive opinion of lecanemab

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA,

Reuters on MSN · 3d

EU regulator completes safety review of Eisai-Biogen's Alzheimer's drug without changes

The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's drug Leqembi without finding the need for any changes to the drug's status.

13h

Eisai, Biogen announce TGA of Australia declined approval of lecanemab

Eisai (ESAIY) and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA, of Australia has confirmed the initial decision to ...

STAT10h

Pharmalittle: We’re reading about HHS reducing public comment, a Lilly obesity drug ad, and more

HHS Secretary Robert F. Kennedy Jr. is proposing to strip public participation from much of the business his agency conducts ...

pharmaphorum12h

Australia stands firm on 'no' to Alzheimer's drug Leqembi

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

Drugmaker Eisai will cut 57 jobs at North Jersey headquarters

Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records show, as the pharmaceutical company shaves off 7% of its U.S workforce.

FiercePharma4d

Eisai to part ways with 121 employees amid new US restructuring effort

Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...

LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight

LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. With an aging population and limited ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results